These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29435471)

  • 1. HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe.
    Chimbetete C; Katzenstein D; Shamu T; Spoerri A; Estill J; Egger M; Keiser O
    Open Forum Infect Dis; 2018 Feb; 5(2):ofy005. PubMed ID: 29435471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment.
    Kouamou V; Varyani B; Shamu T; Mapangisana T; Chimbetete C; Mudzviti T; Manasa J; Katzenstein D
    AIDS Res Hum Retroviruses; 2020 Jul; 36(7):566-573. PubMed ID: 32138527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
    Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
    Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
    Musengimana G; Tuyishime E; Kiromera A; Malamba SS; Mulindabigwi A; Habimana MR; Baribwira C; Ribakare M; Habimana SD; DeVos J; Mwesigwa RCN; Kayirangwa E; Semuhore JM; Rwibasira GN; Suthar AB; Remera E
    Antivir Ther; 2022 Jun; 27(3):13596535221102690. PubMed ID: 35593031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
    Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A;
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
    Avihingsanon A; Hughes MD; Salata R; Godfrey C; McCarthy C; Mugyenyi P; Hogg E; Gross R; Cardoso SW; Bukuru A; Makanga M; Badal-Aesen S; Mave V; Ndege BW; Fontain SN; Samaneka W; Secours R; Van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Munyanga C; Chagomerana M; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC; Grinsztejn B;
    J Int AIDS Soc; 2022 Jun; 25(6):e25905. PubMed ID: 36039892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
    Grinsztejn B; Hughes MD; Ritz J; Salata R; Mugyenyi P; Hogg E; Wieclaw L; Gross R; Godfrey C; Cardoso SW; Bukuru A; Makanga M; Faesen S; Mave V; Wangari Ndege B; Nerette Fontain S; Samaneka W; Secours R; van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Avihingsanon A; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC;
    Lancet HIV; 2019 Sep; 6(9):e588-e600. PubMed ID: 31371262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
    Paton NI; Musaazi J; Kityo C; Walimbwa S; Hoppe A; Balyegisawa A; Asienzo J; Kaimal A; Mirembe G; Lugemwa A; Ategeka G; Borok M; Mugerwa H; Siika A; Odongpiny ELA; Castelnuovo B; Kiragga A; Kambugu A;
    Lancet HIV; 2022 Jun; 9(6):e381-e393. PubMed ID: 35460601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.
    Hosseinipour MC; van Oosterhout JJ; Weigel R; Phiri S; Kamwendo D; Parkin N; Fiscus SA; Nelson JA; Eron JJ; Kumwenda J
    AIDS; 2009 Jun; 23(9):1127-34. PubMed ID: 19417582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
    Kouamou V; Manasa J; Katzenstein D; McGregor AM; Ndhlovu CE; Makadzange AT
    AIDS; 2019 Sep; 33(11):1729-1737. PubMed ID: 31361272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific.
    Ross J; Jiamsakul A; Kumarasamy N; Azwa I; Merati TP; Do CD; Lee MP; Ly PS; Yunihastuti E; Nguyen KV; Ditangco R; Ng OT; Choi JY; Oka S; Sohn AH; Law M
    HIV Med; 2021 Mar; 22(3):201-211. PubMed ID: 33151020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.
    Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Casado JL;
    Infect Dis (Lond); 2020 Mar; 52(3):202-206. PubMed ID: 31760833
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
    Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
    HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia.
    Jiamsakul A; Sungkanuparph S; Law M; Kantor R; Praparattanapan J; Li PC; Phanuphak P; Merati T; Ratanasuwan W; Lee CK; Ditangco R; Mustafa M; Singtoroj T; Kiertiburanakul S;
    J Int AIDS Soc; 2014; 17(1):19053. PubMed ID: 25141905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes.
    Moorhouse M; Maartens G; Venter WDF; Moosa MY; Steegen K; Jamaloodien K; Fox MP; Conradie F
    J Acquir Immune Defic Syndr; 2019 Jan; 80(1):73-78. PubMed ID: 30334876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
    Kityo C; Thompson J; Nankya I; Hoppe A; Ndashimye E; Warambwa C; Mambule I; van Oosterhout JJ; Wools-Kaloustian K; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS; Paton NI;
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):e45-e54. PubMed ID: 28129253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.